Page 70 - CIBERSAM-2015-eng

Research Groups
Group 21
Programme: Depression / Psychosomatic, Anxiety and Impulse Control Disorders
Lead Researcher: Pérez Solá, Víctor
Group Members
STAFF MEMBERS: Allende Leal, Saiko | Grasa Bello, Eva M | Justicia Díaz, Azucena | Pujol Nuez, Jesús.
ASSOCIATED MEMBERS: Alonso Solís, Ana | Álvarez Martínez, Enrique | Antonijoan Arbos, Rosa María
| Arranz Calderón, María Jesús | Bergé Baquero, Daniel | Bulbena Vilarrasa, Antonio | Clos Batet, Susana | Córcoles Martínez, David | Corripio Collado, Iluminada | de Diego Adeliño, Francisco Javier | Durán-Sindreu Terol, Santiago | Elices Armand Ugon, Matilde | Feliu Soler, Albert | Fullana Rivas, Miquel Àngel | Giménez Badia, Sandra | Martín Blanco, Ana | Oller Canet, Sílvia | Pascual Mateos, Juan Carlos | Pérez Blanco, Josefina | Pérez de los Cobos Peris, José | Pérez Egea, Rosario | Portella Moll, María Jesús | Puigdemont Campos, Dolors | Ramos Ferraz, Liliana | Riba Serrano, Jordi | Sauras Quetcuti, Rosa Blanca | Serra Blasco, Maria | Soler Ribaudi, Joaquín | Tiana Sastre, Thais | Trujols Albet, Joan | Valle Cano, Marta.
COLLABORATORS: Ballester Verneda, M Rosa | Gich Saladich, Ignacio José | Romero Lafuente, Sergio. Main lines of research
Permanent research lines:
• Affective disorders: new therapeutic strategies in treatment-resistant major depression; Deep Brain Stimulation in Treatment Resistant Major Depression; structural neuroimaging; treatment resistance biological and genetic biomarkers; identification and evaluation of new therapeutic targets and programs; pharmacogenetics; ICT application and new technologies in the preven- tion and treatment of depression.
• Psychotic disorders: efficacy and effectiveness of 70 I Annual report 2015 I CIBERSAM
antipsychotic drugs; first episodes of psychosis; genotype-phenotype and environment interac- tion; neuroimaging; pharmacogenetics; ICT and Apps in m-health for treatment resistant schizo- phrenia; Deep Brain Stimulation in Treatment Re- sistant Schizophrenia.
• Personality disorders: mixed treatment in pa- tients with Borderline Personality Disorder (BPD), validation of diagnostic instruments; genetic-en- vironment studies; structural and functional neu- roimaging studies on mindfulness effects.